Renhe Pharmaceutical announced that since November 14, 2025, revealed that the controlling shareholder Renhe Group plans to reduce its holdings by no more than 3 million shares, accounting for 0.2143% of the total share capital, as of the disclosure date of this announcement, Renhe Group has not actually reduced its holdings. The shareholding is still 325 million shares, accounting for 23.2367%. It has now decided to terminate the holdings reduction plan early.

Renhe Pharmaceutical announced that since November 14, 2025, revealed that the controlling shareholder Renhe Group plans to reduce its holdings by no more than 3 million shares, accounting for 0.2143% of the total share capital, as of the disclosure date of this announcement, Renhe Group has not actually reduced its holdings. The shareholding is still 325 million shares, accounting for 23.2367%. It has now decided to terminate the holdings reduction plan early.